5 results match your criteria: "Hospital Universitario Cruces. Instituto de Investigación Sanitaria BioBizkaia[Affiliation]"
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
Gut
January 2025
Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain
Background And Objectives: Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it.
Secondary Objectives: to evaluate the effect of anti-TNF withdrawal on relapse-free time, endoscopic and radiological activity, safety, quality of life and work productivity; and to identify predictive factors for relapse.
Design: Prospective, quadruple-blind, multicentre, randomised, controlled trial.
If triage works, the ED works.
An Pediatr (Engl Ed)
December 2024
Servicio de Urgencias de Pediatría, Hospital Universitario Cruces, Instituto de Investigación Sanitaria BioBizkaia, Universidad del País Vasco, UPV/EHU, Barakaldo, Vizcaya, Spain. Electronic address:
Prognostic significance of mutation type and chromosome fragility in Fanconi anemia.
Am J Hematol
February 2025
Joint Research Unit on Genomic Medicine, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU, Barcelona, Spain.
Article Synopsis
- Fanconi anemia (FA) is a rare genetic disorder marked by varying symptoms and significant chromosome fragility, leading to severe health issues like cancer and bone marrow failure.
- The Spanish Registry of Patients with FA gathered data from 227 patients over 30 years, revealing an 86% cumulative cancer incidence by age 50, with outcomes differing based on chromosome fragility and specific gene mutations.
- Findings suggest that patients with mutations allowing some protein function (genetic hypomorphism) tend to have better health outcomes, indicating potential for new therapies that could enhance mutant FA protein function to improve patient prognosis.
[Advances and Challenges in Multidrug Resistant Tuberculosis (MDR-TB) Control].
Open Respir Arch
May 2024
Servicio de Neumología, Hospital Universitario Cruces. Instituto de Investigación Sanitaria BioBizkaia, Barakaldo, Bizkaia, España.
Criteria and indicators to evaluate quality of care in genitourinary tumour boards.
Clin Transl Oncol
July 2024
Fundación ECO (Excelencia y Calidad de La Oncología), Madrid, Spain.
Purpose: Genitourinary (GU) multidisciplinary tumour boards (GUMTBs) are key components of patient care, as they might lead to changes in treatment plan, improved survival, and increased adherence to guidelines. However, there are no guidelines on how GUMTBs should operate or how to assess their quality of performance.
Methods: A systematic literature review was conducted to identify criteria and indicators to evaluate quality in GUMTBs.